Avadel Pharmaceuticals (AWK) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AWK Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Avadel

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AWK Stock 12 Month Forecast

Average Price Target

€17.44

▲(36.22% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Avadel Pharmaceuticals in the last 3 months. The average price target is €17.44 with a high forecast of €30.71 and a low forecast of €13.65. The average price target represents a 36.22% change from the last price of €12.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","31":"€31","12.25":"€12.25","18.5":"€18.5","24.75":"€24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.70873188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.4357355452,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.64832528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.25,18.5,24.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,13.900671683076922,15.301343366153846,16.70201504923077,18.102686732307692,19.503358415384614,20.90403009846154,22.304701781538462,23.705373464615384,25.106045147692306,26.50671683076923,27.907388513846154,29.308060196923076,{"y":30.70873188,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,12.879671965015385,13.25934393003077,13.639015895046153,14.018687860061538,14.398359825076923,14.778031790092308,15.157703755107693,15.537375720123077,15.917047685138462,16.296719650153847,16.67639161516923,17.056063580184617,{"y":17.4357355452,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,12.588332713846153,12.676665427692308,12.764998141538461,12.853330855384616,12.94166356923077,13.029996283076922,13.118328996923077,13.20666171076923,13.294994424615384,13.383327138461539,13.471659852307692,13.559992566153847,{"y":13.64832528,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€30.71

Average Price Target€17.44

Lowest Price Target€13.65

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

09/18/25

Craig-Hallum Sticks to Their Buy Rating for Avadel Pharmaceuticals (AVDL)

Benjamin Burnett

Wells Fargo

€13.67

Hold

6.81%

Upside

Reiterated

09/18/25

Wells Fargo Reaffirms Their Hold Rating on Avadel Pharmaceuticals (AVDL)

Ram Selvaraju

H.C. Wainwright

€30.76

Buy

140.33%

Upside

Reiterated

09/17/25

Avadel Pharmaceuticals (AVDL) Receives a Buy from H.C. Wainwright

Francois Brisebois

LifeSci Capital

€17.94→€18.8

Buy

46.87%

Upside

Reiterated

09/17/25

Positive Outlook for Avadel Pharmaceuticals Amid Legal Resolution and Strategic Growth Initiatives

David Amsellem

Piper Sandler

€13.67

Buy

6.81%

Upside

Reiterated

09/05/25

Piper Sandler Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/04/25

Avadel Pharmaceuticals: Positioned for Growth with Lumryz and Strategic Acquisitions

Bryce Generon

TR | OpenAI - 4o

€12.82→€14.1

Buy

10.15%

Upside

Upgraded

09/04/25

AI Generated ArticleAI Generated Article

Ashwani Verma

UBS

€11.11→€17.09

Buy

33.52%

Upside

Reiterated

08/21/25

Avadel Pharmaceuticals price target raised to $20 from $13 at UBSAvadel Pharmaceuticals price target raised to $20 from $13 at UBS

David Hoang

Deutsche Bank

€13.67→€15.38

Buy

20.17%

Upside

Reiterated

08/08/25

Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche BankAvadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank

Ami Fadia

Needham

€18.8→€16.24

Buy

26.84%

Upside

Reiterated

08/07/25

Needham Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

09/18/25

Craig-Hallum Sticks to Their Buy Rating for Avadel Pharmaceuticals (AVDL)

Benjamin Burnett

Wells Fargo

€13.67

Hold

6.81%

Upside

Reiterated

09/18/25

Wells Fargo Reaffirms Their Hold Rating on Avadel Pharmaceuticals (AVDL)

Ram Selvaraju

H.C. Wainwright

€30.76

Buy

140.33%

Upside

Reiterated

09/17/25

Avadel Pharmaceuticals (AVDL) Receives a Buy from H.C. Wainwright

Francois Brisebois

LifeSci Capital

€17.94→€18.8

Buy

46.87%

Upside

Reiterated

09/17/25

Positive Outlook for Avadel Pharmaceuticals Amid Legal Resolution and Strategic Growth Initiatives

David Amsellem

Piper Sandler

€13.67

Buy

6.81%

Upside

Reiterated

09/05/25

Piper Sandler Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/04/25

Avadel Pharmaceuticals: Positioned for Growth with Lumryz and Strategic Acquisitions

Bryce Generon

TR | OpenAI - 4o

€12.82→€14.1

Buy

10.15%

Upside

Upgraded

09/04/25

AI Generated ArticleAI Generated Article

Ashwani Verma

UBS

€11.11→€17.09

Buy

33.52%

Upside

Reiterated

08/21/25

Avadel Pharmaceuticals price target raised to $20 from $13 at UBSAvadel Pharmaceuticals price target raised to $20 from $13 at UBS

David Hoang

Deutsche Bank

€13.67→€15.38

Buy

20.17%

Upside

Reiterated

08/08/25

Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche BankAvadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank

Ami Fadia

Needham

€18.8→€16.24

Buy

26.84%

Upside

Reiterated

08/07/25

Needham Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avadel Pharmaceuticals

1 Month

xxx

Success Rate

15/27 ratings generated profit

Average Return

+3.81%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +3.81% per trade.

3 Months

xxx

Success Rate

17/28 ratings generated profit

Average Return

+11.78%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.71% of your transactions generating a profit, with an average return of +11.78% per trade.

1 Year

Chase KnickerbockerCraig-Hallum

Success Rate

15/20 ratings generated profit

Average Return

+36.68%

reiterated a buy rating 13 days ago

Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +36.68% per trade.

2 Years

xxx

Success Rate

24/28 ratings generated profit

Average Return

+74.46%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +74.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AWK Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AWK has received 18 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. AWK average Analyst price target in the past 3 months is 17.44.

Each month's total comprises the sum of three months' worth of ratings.

AWK Financial Forecast

AWK Earnings Forecast

Next quarter’s earnings estimate for AWK is €0.06 with a range of €0.03 to €0.13. The previous quarter’s EPS was €0.09. AWK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AWK has Preformed in-line its overall industry.

AWK Sales Forecast

Next quarter’s sales forecast for AWK is €62.87M with a range of €61.97M to €63.83M. The previous quarter’s sales results were €58.22M. AWK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AWK has Preformed in-line its overall industry.

AWK Stock Forecast FAQ

What is DE:AWK’s average 12-month price target, according to analysts?

Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is 17.44.

What is DE:AWK’s upside potential, based on the analysts’ average price target?

Avadel Pharmaceuticals has 36.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Avadel Pharmaceuticals a Buy, Sell or Hold?

Avadel Pharmaceuticals has a consensus rating of Strong Buy, which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Avadel Pharmaceuticals’s share price target?

The average share price target for Avadel Pharmaceuticals is 17.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €30.71 ,and the lowest forecast is €13.65. The average share price target represents 36.22% Increase from the current price of €12.8.

What do analysts say about Avadel Pharmaceuticals?

Avadel Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Avadel Pharmaceuticals?

To buy shares of DE:AWK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avadel Pharmaceuticals (AWK) Stock Forecast & Price Target

AWK Analyst Ratings

AWK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avadel Pharmaceuticals

AWK Analyst Recommendation Trends

AWK Financial Forecast

AWK Earnings Forecast

AWK Sales Forecast

AWK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts